Top entities: Brazil, Urban Institute, Alexandre Padilha, Brazil — Brazilian Health Regulatory Agency, TAK-003.

What category does this event fall under?

Regulatory — classified as vaccine suspension.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Brazil suspended use · Urban Institute developed vaccine · Brazil — Brazilian Health Regulatory Agency approved vaccine

Is this event still developing?

This is an active story, last updated Jun 09, 2026. Coverage continues to evolve.

Regulatory vaccine suspension

Brazil Suspends Single-Dose Dengue Vaccine

Q: When did this event occur?

First reported Jun 08, 2026; last updated Jun 09, 2026.

Q: What is the market impact?

Direct. The temporary suspension of Brazil's single-dose dengue vaccine could negatively impact the stock prices of pharmaceutical companies involved in its development and distribution, such as the Urban Institute.

Analysis based on 7 articles · First reported Jun 08, 2026 · Last updated Jun 09, 2026

Sentiment

-50

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The temporary suspension of Brazil's single-dose dengue vaccine could negatively impact the stock prices of pharmaceutical companies involved in its development and distribution, such as the Urban Institute. Conversely, companies like Takeda Pharmaceutical Company, which produce alternative dengue vaccines, might see a positive market reaction due to increased demand for their products.

Pharmaceuticals Healthcare

Event Summary

Brazil has temporarily suspended the use of its single-dose dengue vaccine after two suspicious deaths and 42 severe reactions were reported among the more than half a million people vaccinated. Health Minister Alexandre Padilha stated that while there is no conclusive data linking the vaccine to these cases, the suspension is a precautionary measure. The vaccine, developed by the Urban Institute and approved by Brazil — Brazilian Health Regulatory Agency in late 2025, had shown high efficacy in trials. This decision impacts Brazil's public health efforts against dengue, which caused over 6,000 deaths in 2024, and could affect future collaborations with entities like WuXi AppTec for vaccine production. The alternative two-dose vaccine from Takeda Pharmaceutical Company (TAK-003) remains in use.

Key Actions

100 Brazil suspended use

80 Urban Institute developed vaccine

40 Brazil — Brazilian Health Regulatory Agency approved vaccine

30 Brazil plans expand production WuXi AppTec

Entities Involved

cnt

Brazil

Brazil temporarily suspended the use of its single-dose dengue vaccine due to two suspicious deaths and severe reactions, impacting its public health initiatives and potentially its reputation in vaccine development.

Importance 100 Sentiment -40

ngo

Urban Institute

The Urban Institute developed the single-dose dengue vaccine, and its reputation and future production plans are directly affected by the suspension and ongoing investigation.

Importance 80 Sentiment -60

per

Alexandre Padilha

Alexandre Padilha, the Health Minister of Brazil, announced the temporary suspension of the dengue vaccine as a precautionary measure, emphasizing the lack of conclusive data linking the deaths to the vaccine.

Importance 70 Sentiment -20

govactor

Brazil — Brazilian Health Regulatory Agency

Brazil — Brazilian Health Regulatory Agency, Brazil's regulatory agency, approved the vaccine in late 2025, and the suspension raises questions about its initial approval process.

Importance 40 Sentiment -10

oth

TAK-003

TAK-003 is another dengue vaccine that requires two doses and is still in use, potentially benefiting from the suspension of Brazil's single-dose vaccine.

Importance 30 Sentiment 20

stock

Takeda Pharmaceutical Company

Takeda is the Japanese laboratory that produces another dengue vaccine, which continues to be used without problems in Brazil, potentially seeing increased demand due to the suspension of the local vaccine.

Importance 30 Sentiment 20

stock

WuXi AppTec

WuXi is a Chinese laboratory with which Brazil plans to expand vaccine production, and the suspension could affect these future plans.

Importance 20 Sentiment 0

ngo

World Health Organization

The World Health Organization is mentioned as a source of information regarding the TAK-003 vaccine, but it is not directly impacted by Brazil's vaccine suspension.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard